Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
BURLINGAME, Calif., Sept. 14, 2017 -- Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Five Prime Therapeutics, Inc. (NASDAQ:FPRX). The non-exclusive license grants Five Prime rights to use the AlivaMab Mouse for antibody drug discovery and development.
“Ablexis is pleased to add Five Prime to the list of leading biopharmaceutical companies that are using the AlivaMab Mouse,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “The AlivaMab Mouse is already being used by the majority of the world’s top 15 pharmaceutical companies, more than any other next generation antibody discovery platform. Now, with newly added licensing flexibility, Ablexis continues expanding the licensing of the AlivaMab Mouse for the rapid and efficient discovery of antibody drug candidates that meet target product profiles for activity, specificity and developability.”
About Ablexis, LLC
Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple companies and continues making the AlivaMab Mouse available via non-exclusive licenses. More information can be found by visiting the Company’s website at www.ablexis.com.
Ablexis Corporate Contact: Ablexis, LLC Larry Green, (415) 967-1220 [email protected] Ablexis Media Contact: Red House Communications Denise Powell, (510) 703-9491 [email protected]
